MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jamanetworkopen.2024.48215

Медицинская библиотека · JAMA network open · 2024

Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial.

Collins Sean P, Shotwell Matthew S, Strich Jeffrey R, Gibbs Kevin W, de Wit Marjolein, Files D Clark, Harkins Michelle, Hudock Kris, Merck Lisa H, Moskowitz Ari, Apodaca Krystle D, Barksdale Aaron, Safdar Basmah, Javaheri Ali, Sturek Jeffrey M, Schrager Harry, Iovine Nicole M, Tiffany Brian, Douglas Ivor, Levitt Joseph, Ginde Adit A, Hager David N, Shapiro Nathan, Duggal Abhijit, Khan Akram, Lanspa Michael, Chen Peter, Gentile Nina, Harris Estelle, Gong Michelle, Sellers Subhashini, Goodwin Andrew J, Tidswell Mark A, Filbin Michael, Desai Neeraj, Gutiérrez Felix, Estrada Vicente, Burgos Joaquin, Boyles Tom, Paño-Pardo Jose R, Hussen Nazreen, Rosenberg Yves, Troendle James, Bernard Gordon R, Bistran-Hall Amanda J, Walsh Kelly, Casey Jonathan D, DeClercq Josh, Joly Meghan Morrison, Pulley Jill, Rice Todd W, Schildcrout Jonathan S, Wang Li, Semler Matthew W, Self Wesley H, ACTIV-4 Host Tissue Investigators

СтатьяРандомизированное исследованиеМногоцентровое исследованиеКлиническое исследование III фазыПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

IMPORTANCE

Fostamatinib, a spleen tyrosine kinase inhibitor, has been reported to improve outcomes of COVID-19.

OBJECTIVE

To evaluate the efficacy and safety of fostamatinib in adults hospitalized with COVID-19 and hypoxemia.

DESIGN, SETTING, AND

PARTICIPANTS

This multicenter, phase 3, placebo-controlled, double-blinded randomized clinical trial was conducted at 41 US sites and 21 international sites between November 17, 2021, and September 27, 2023; the last follow-up visit was December 31, 2023. Participants were adults aged 18 years or older hospitalized with acute SARS-CoV-2 infection and hypoxemia. Data were analyzed between January 10 and March 8, 2024.

INTERVENTIONS: Fostamatinib, 150 mg orally twice daily for 14 days, or placebo.

MAIN OUTCOMES AND MEASURES: The primary outcome was oxygen-free days, an ordinal outcome classifying a participant's status at day 28 based on mortality and duration of supplemental oxygen use. An adjusted odds ratio (AOR) greater than 1.0 was considered to indicate superiority of fostamatinib over placebo. A key secondary outcome was 28-day all-cause mortality. Safety outcomes included elevated transaminase values, neutropenia, and hypertension.

RESULTS

Of the 400 participants randomized (median age, 67 years [IQR, 58-76 years]; 210 [52.5%] men), 199 received fostamatinib and 201 received placebo. The mean (SD) number of oxygen-free days was 13.4 (12.4) in the fostamatinib group and 14.2 (12.1) in the placebo group (unadjusted mean difference, -1.26 days [95% CI, -3.52 to 1.00 days]; AOR, 0.82 [95% credible interval (CrI), 0.58-1.17]). Mortality at 28 days occurred in 22 of 195 patients (11.3%) in the fostamatinib group and 16 of 197 (8.1%) in the placebo group (AOR, 1.44; 95% CrI, 0.72-2.90). Aspartate aminotransferase elevation occurred more commonly in the fostamatinib group (23 [11.6%]) than in the placebo group (11 [5.5%]; AOR, 2.28; 95% CrI, 1.07-4.84). Other safety outcomes were similar between groups.

CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of adults hospitalized with COVID-19 and hypoxemia, fostamatinib did not increase the number of oxygen-free days compared with placebo. These results do not support the hypothesis that fostamatinib improves outcomes among adults hospitalized with hypoxemia during the Omicron era.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04924660.

Для цитирования: Collins Sean P, Shotwell Matthew S, Strich Jeffrey R, Gibbs Kevin W, de Wit Marjolein, Files D Clark, Harkins Michelle, Hudock Kris, Merck Lisa H, Moskowitz Ari, Apodaca Krystle D, Barksdale Aaron, Safdar Basmah, Javaheri Ali, Sturek Jeffrey M, Schrager Harry, Iovine Nicole M, Tiffany Brian, Douglas Ivor, Levitt Joseph, Ginde Adit A, Hager David N, Shapiro Nathan, Duggal Abhijit, Khan Akram, Lanspa Michael, Chen Peter, Gentile Nina, Harris Estelle, Gong Michelle, Sellers Subhashini, Goodwin Andrew J, Tidswell Mark A, Filbin Michael, Desai Neeraj, Gutiérrez Felix, Estrada Vicente, Burgos Joaquin, Boyles Tom, Paño-Pardo Jose R, Hussen Nazreen, Rosenberg Yves, Troendle James, Bernard Gordon R, Bistran-Hall Amanda J, Walsh Kelly, Casey Jonathan D, DeClercq Josh, Joly Meghan Morrison, Pulley Jill, Rice Todd W, Schildcrout Jonathan S, Wang Li, Semler Matthew W, Self Wesley H, ACTIV-4 Host Tissue Investigators. Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial.. JAMA network open. 2024. DOI: 10.1001/jamanetworkopen.2024.48215.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.